Cargando…
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting
Serum neurofilament light chain (sNfL) is an intensely investigated biomarker in multiple sclerosis (MS). The aim of this study was to explore the impact of cladribine (CLAD) on sNfL and the potential of sNfL as a predictor of long-term treatment response. Data were gathered from a prospective, real...
Autores principales: | Seiberl, Michael, Feige, Julia, Hilpold, Patrick, Hitzl, Wolfgang, Machegger, Lukas, Buchmann, Arabella, Khalil, Michael, Trinka, Eugen, Harrer, Andrea, Wipfler, Peter, Moser, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961994/ https://www.ncbi.nlm.nih.gov/pubmed/36835478 http://dx.doi.org/10.3390/ijms24044067 |
Ejemplares similares
-
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery
por: Feige, Julia, et al.
Publicado: (2022) -
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
por: Moser, Tobias, et al.
Publicado: (2021) -
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients
por: Moser, Tobias, et al.
Publicado: (2021) -
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study
por: Moser, Tobias, et al.
Publicado: (2022) -
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis
por: Moser, Tobias, et al.
Publicado: (2021)